CA
NZ
UK
AU
IND
US
Seres (NASDAQ:MCRB) Therapeutics has spent two years shedding assets, staff and debt while betting its remaining cash on early-stage microbiome programs. New SER-155 data in a cancer-related bowel complication, alongside cash-preserving deals with Nestlé Health Science, mark the latest turns in a company still …
Reviva Pharmaceuticals Holdings, Inc. (OTC:RVPH) is racing toward two pivotal 2026 readouts for brilaroxazine, its lead schizophrenia candidate, even as it navigates a Nasdaq delisting, a reverse split and a going-concern warning. A March 2026 raise pushed cash to $22.2 million, but that only …
Scienture Holdings, Inc. (NASDAQ:SCNX), the specialty pharmaceutical company assembled from the 2024 merger of TRxADE Health and Scienture, Inc., is pushing its FDA-approved naloxone nasal spray REZENOPY toward a commercial debut. A dedicated sales force is set to begin work on June 1, 2026, …
Moleculin Biotech (NASDAQ:MBRX) says preliminary, unblinded data from the first 45 patients in its pivotal MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory AML beat a concurrent control arm on remission rates. An independent monitoring committee recommended the study continue. The signal …
Neuronetics (NASDAQ:STIM) has named Nir Naor, a former Axogen finance chief credited with steering that company to profitability, as its new Chief Financial Officer. The move lands as the combined NeuroStar-and-Greenbrook mental-health platform posts narrowing losses, faster clinic growth and a revenue covenant the …
NeuroOne Medical Technologies (NASDAQ:NMTC) markets the only FDA-cleared electrode platform that both records brain activity and delivers radiofrequency ablation through the same implanted device. Its OneRF system is expanding from epilepsy into facial pain, while a Zimmer Biomet distribution partnership drives sales. But a …
NeuroSense Therapeutics (NASDAQ:NRSN) is pushing its lead ALS candidate, PrimeC, toward a Canadian New Drug Submission after a Phase 2b study showed slower functional decline and a survival signal. The clinical story has strengthened through 2026, but it remains a small, thinly capitalized biotech …
NEXGEL, Inc. (NASDAQ:NXGL), a Pennsylvania hydrogel maker, published clinical data on May 19, 2026 showing its laser-treatment patch cut plume concentration by 95.6% during laser hair removal. The finding lands weeks after the company closed a transformative acquisition that formed BIONX Surgical, even as …
Niagen Bioscience, (NASDAQ:NAGE) the healthy-aging company once known as ChromaDex, built a profitable supplement business around its patented NAD+ ingredient, Niagen. Now, through a new pharmaceutical subsidiary, it is chasing something harder: an approved drug for a rare pediatric disease that currently has no …
LifeMD (NASDAQ:LFMD) enters the second half of 2026 leaning almost entirely on telehealth after divesting the WorkSimpli software unit last November. First-quarter results showed record subscriber growth and a resurgent weight-management franchise built around branded GLP-1 partnerships, but marketing spend widened the adjusted EBITDA …
Please wait processing your request...